VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+5.59%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$169M
AUM Growth
-$13M
(-7.2%)
Cap. Flow
-$16.1M
Cap. Flow
% of AUM
-9.55%
Top 10 Holdings %
Top 10 Hldgs %
6.26%
Holding
495
New
55
Increased
122
Reduced
257
Closed
60
Top Buys
| 1 |
NVIDIA
NVDA
|
$1.21M |
| 2 |
Netflix
NFLX
|
$1.05M |
| 3 |
Meta Platforms (Facebook)
META
|
$1.04M |
| 4 |
Adobe
ADBE
|
$995K |
| 5 |
Applied Materials
AMAT
|
$977K |
Top Sells
| 1 |
ATVI
Activision Blizzard Inc.
ATVI
|
$1.01M |
| 2 |
Progressive
PGR
|
$999K |
| 3 |
Stryker
SYK
|
$984K |
| 4 |
Republic Services
RSG
|
$973K |
| 5 |
Linde
LIN
|
$966K |
Sector Composition
| 1 | Healthcare | 27.98% |
| 2 | Technology | 15.96% |
| 3 | Financials | 11.34% |
| 4 | Energy | 8.43% |
| 5 | Industrials | 8.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
401
Day One Biopharmaceuticals
DAWN
$773M
| $96.4K | 0.06% |
8,073
+3,388
| +72% | +$40.5K |
|
402
RAPT Therapeutics
RAPT
$214M
| $96.4K | 0.06% |
644
-44
| -6% | -$6.58K |
|
403
89bio
ETNB
$1.32B
| $96.3K | 0.06% |
+5,084
| New | +$96.3K |
|
404
Crinetics Pharmaceuticals
CRNX
$3.35B
| $96.1K | 0.06% |
5,333
-882
| -14% | -$15.9K |
|
|
AMRS
405
DELISTED
Amyris Inc.
AMRS
| $95.7K | 0.06% |
92,939
+35,454
| +62% | +$36.5K |
|
406
Fate Therapeutics
FATE
$116M
| $95.3K | 0.06% |
20,025
+13,440
| +204% | +$64K |
|
407
Rocket Pharmaceuticals
RCKT
$354M
| $95.2K | 0.06% |
4,792
+351
| +8% | +$6.97K |
|
|
AGEN
408
Agenus
AGEN
$138M
| $95.1K | 0.06% |
2,971
+1,054
| +55% | +$33.7K |
|
409
AbCellera Biologics
ABCL
$1.26B
| $95.1K | 0.06% |
14,714
+4,731
| +47% | +$30.6K |
|
410
Viridian Therapeutics
VRDN
$1.53B
| $93.5K | 0.06% |
3,930
+307
| +8% | +$7.3K |
|
|
EXAI
411
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $92.8K | 0.06% |
+15,668
| New | +$92.8K |
|
412
Stoke Therapeutics
STOK
$1.13B
| $92.2K | 0.05% |
8,678
-3,400
| -28% | -$36.1K |
|
413
Akero Therapeutics
AKRO
$3.58B
| $92K | 0.05% |
1,971
-318
| -14% | -$14.8K |
|
414
Arvinas
ARVN
$575M
| $91.8K | 0.05% |
3,699
+1,011
| +38% | +$25.1K |
|
415
Ardelyx
ARDX
$1.57B
| $91.7K | 0.05% |
+27,049
| New | +$91.7K |
|
416
Arcellx
ACLX
$4.03B
| $90.6K | 0.05% |
2,866
-202
| -7% | -$6.39K |
|
417
4D Molecular Therapeutics
FDMT
$340M
| $89K | 0.05% |
4,923
+783
| +19% | +$14.1K |
|
418
ALX Oncology
ALXO
$65.3M
| $88.6K | 0.05% |
11,794
+2,775
| +31% | +$20.8K |
|
419
Edgewise Therapeutics
EWTX
$1.64B
| $88.5K | 0.05% |
11,422
-1,085
| -9% | -$8.41K |
|
420
Scilex Holding
SCLX
$159M
| $88.4K | 0.05% |
504
| – | – |
|
421
Iovance Biotherapeutics
IOVA
$901M
| $88.3K | 0.05% |
12,542
-2,467
| -16% | -$17.4K |
|
422
Aldeyra Therapeutics
ALDX
$334M
| $87.3K | 0.05% |
+10,401
| New | +$87.3K |
|
423
Seres Therapeutics
MCRB
$169M
| $85.1K | 0.05% |
888
+71
| +9% | +$6.81K |
|
424
Alector
ALEC
$305M
| $84.8K | 0.05% |
14,104
+3,322
| +31% | +$20K |
|
425
Kodiak Sciences
KOD
$556M
| $83.1K | 0.05% |
12,042
-1,838
| -13% | -$12.7K |
|